Acute and chronic antiparkinsonian effects of the novel nociceptin/ orphanin FQ receptor antagonist NiK-21273 in comparison with SB-612111

British Journal of Pharmacology

Volumn 168, Issue 4, 2013, Pages 863-879

  Marti, M ^a   Mela, F ^a   Budri, M ^a   Volta, M ^a   Malfacini, D ^a   Molinari, S ^a   Zaveri, N T ^b   Ronzoni, S ^c   Petrillo, P ^c   Calo G ^a   Morari, M ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b Astraea Therapeutics Inc   (Spain)

^c NiKem Research   (Italy)

Author keywords

6 hydroxydopamine; L DOPA; NiK 21273; nociceptin orphanin FQ; NOP antagonist; Parkinson's disease; reserpine SB 612111

Indexed keywords

7 [4 (2,6 DICHLOROPHENYL) 1 PIPERIDINYLMETHYL] 6,7,8,9 TETRAHYDRO 1 METHYL 5H BENZOCYCLOHEPTEN 5 OL; BENSERAZIDE; LEVODOPA; NIK 21273; NOCICEPTIN RECEPTOR; NOCICEPTIN RECEPTOR ANTAGONIST; OXIDOPAMINE; RESERPINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LINE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG POTENTIATION; DRUG SELECTIVITY; HYPOKINESIA; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MALE; MOTOR PERFORMANCE; MOUSE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; TREATMENT OUTCOME; VAS DEFERENS;

ANIMALS; ANTIPARKINSON AGENTS; BEHAVIOR, ANIMAL; CALCIUM; CHO CELLS; CRICETINAE; CRICETULUS; CYCLOHEPTANES; DOSE-RESPONSE RELATIONSHIP, DRUG; INDOLES; MALE; MICE; MICE, INBRED STRAINS; MOTOR ACTIVITY; MUSCLE CONTRACTION; MUSCLE, SMOOTH; PARKINSONIAN DISORDERS; PIPERIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID; RESERPINE; ROTAROD PERFORMANCE TEST; TRANSFECTION; VAS DEFERENS;

EID: 84872946203     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2012.02219.x     Document Type: Article

References (43)

1. Bigoni R, Giuliani S, Calo G, Rizzi A, Guerrini R, Salvadori S, et al. (1999). Characterization of nociceptin receptors in the periphery: in vitro and in vivo studies. Naunyn Schmiedebergs Arch Pharmacol 359: 160-167.
2. Calo G, Rizzi A, Bogoni G, Neugebauer V, Salvadori S, Guerrini R, et al. (1996). The mouse vas deferens: a pharmacological preparation sensitive to nociceptin. Eur J Pharmacol 311: R3-R5.
3. Calo G, Guerrini R, Rizzi A, Salvadori S, Regoli D, (2000). Pharmacology of nociceptin and its receptor: a novel therapeutic target. Br J Pharmacol 129: 1261-1283.
4. Camarda V, Fischetti C, Anzellotti N, Molinari P, Ambrosio C, Kostenis E, et al. (2009). Pharmacological profile of NOP receptors coupled with calcium signaling via the chimeric protein G alpha qi5. Naunyn Schmiedebergs Arch Pharmacol 379: 599-607.
5. Chiou LC, Chuang KC, Wichmann J, Adam G, (2004). Ro 64-6198 [(1S,3aS)-8-(2,3,3a,4,5,6-hexahydro-1H-phenalen-1-yl)-1-phenyl-1,3, 8-triaza-spiro [4.5]decan-4-one] acts differently from nociceptin/orphanin FQ in rat periaqueductal gray slices. J Pharmacol Exp Ther 311: 645-651.
6. Di Benedetto M, Cavina C, D'Addario C, Leoni G, Candeletti S, Cox BM, et al. (2009). Alterations of N/OFQ and NOP receptor gene expression in the substantia nigra and caudate putamen of MPP+ and 6-OHDA lesioned rats. Neuropharmacology 56: 761-767.
7. Fischetti C, Rizzi A, Gavioli EC, Marzola G, Trapella C, Guerrini R, et al. (2009). Further studies on the pharmacological features of the nociceptin/orphanin FQ receptor ligand ZP120. Peptides 30: 248-255.
8. Gouty S, Brown JM, Rosenberger J, Cox BM, (2010). MPTP treatment increases expression of pre-pro-nociceptin/orphanin FQ mRNA in a subset of substantia nigra reticulata neurons. Neuroscience 169: 269-278.
9. Guerrini R, Calo G, Rizzi A, Bianchi C, Lazarus LH, Salvadori S, et al. (1997). Address and message sequences for the nociceptin receptor: a structure-Activity study of nociceptin-(1-13)-peptide amide. J Med Chem 40: 1789-1793.
10. Kenakin T, (2004). Principles: receptor theory in pharmacology. Trends Pharmacol Sci 25: 186-192.
11. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). NC3Rs Reporting Guidelines Working Group. Br J Pharmacol 160: 1577-1579.
12. Kuschinsky K, Hornykiewicz O, (1972). Morphine catalepsy in the rat: relation to striatal dopamine metabolism. Eur J Pharmacol 19: 119-122.
13. Kuzmin A, Sandin J, Terenius L, Ogren SO, (2004). Evidence in locomotion test for the functional heterogeneity of ORL-1 receptors. Br J Pharmacol 141: 132-140.
14. Lambert DG, (2008). The nociceptin/orphanin FQ receptor: a target with broad therapeutic potential. Nat Rev Drug Discov 7: 694-710.
15. Mabrouk OS, Marti M, Morari M, (2010). Endogenous nociceptin/orphanin FQ (N/OFQ) contributes to haloperidol-induced changes of nigral amino acid transmission and parkinsonism: a combined microdialysis and behavioral study in naive and nociceptin/orphanin FQ receptor knockout mice. Neuroscience 166: 40-48.
16. Marti M, Mela F, Bianchi C, Beani L, Morari M, (2002). Striatal dopamine-NMDA receptor interactions in the modulation of glutamate release in the substantia nigra pars reticulata in vivo: opposite role for D1 and D2 receptors. J Neurochem 83: 635-644.
17. Marti M, Mela F, Guerrini R, Calo G, Bianchi C, Morari M, (2004). Blockade of nociceptin/orphanin FQ transmission in rat substantia nigra reverses haloperidol-induced akinesia and normalizes nigral glutamate release. J Neurochem 91: 1501-1504.
18. Marti M, Mela F, Fantin M, Zucchini S, Brown JM, Witta J, et al. (2005). Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease. J Neurosci 25: 9591-9601.
19. Marti M, Trapella C, Viaro R, Morari M, (2007). The nociceptin/orphanin FQ receptor antagonists J-113397 and L-DOPA additively attenuate experimental parkinsonism through overinhibition of the nigrothalamic pathway. J Neurosci 27: 1297-1307.
20. Marti M, Trapella C, Morari M, (2008). The novel nociceptin/orphanin FQ receptor antagonist Trap-101 alleviates experimental parkinsonism through inhibition of the nigro-thalamic pathway: positive interaction with L-DOPA. J Neurochem 107: 1683-1696.
21. Marti M, Sarubbo S, Latini F, Cavallo M, Eleopra R, Biguzzi S, et al. (2010). Brain interstitial nociceptin/orphanin FQ levels are elevated in Parkinson's disease. Mov Disord 25: 1723-1732.
22. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
23. Meunier JC, Mollereau C, Toll L, Suaudeau C, Moisand C, Alvinerie P, et al. (1995). Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature 377: 532-535.
24. Mogil JS, Pasternak GW, (2001). The molecular and behavioral pharmacology of the orphanin FQ/nociceptin peptide and receptor family. Pharmacol Rev 53: 381-415.
25. Norton CS, Neal CR, Kumar S, Akil H, Watson SJ, (2002). Nociceptin/orphanin FQ and opioid receptor-like receptor mRNA expression in dopamine systems. J Comp Neurol 444: 358-368.
26. Okabe C, Murphy NP, (2004). Short-term effects of the nociceptin receptor antagonist Compound B on the development of methamphetamine sensitization in mice: a behavioral and c-fos expression mapping study. Brain Res 1017: 1-12.
27. Paxinos G, Watson C, (1986). The Rat Brain in Stereotaxic Coordinates, 2nd edn. Academic Press: Sydney and Orlando, FL.
28. Reinscheid RK, Nothacker HP, Bourson A, Ardati A, Henningsen RA, Bunzow JR, et al. (1995). Orphanin FQ: a neuropeptide that activates an opioidlike G protein-coupled receptor. Science 270: 792-794.
29. Rizzi A, Gavioli EC, Marzola G, Spagnolo B, Zucchini S, Ciccocioppo R, et al. (2007). Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl) piperidin-1-yl]methyl]-6,7,8,9 -tetrahydro-5H-benzocyclohepten-5-ol]: in vivo studies. J Pharmacol Exp Ther 321: 968-974.
30. Ronzoni S, (2010). Novel potent and selective ORL-1 antagonists with efficacy in animal models of Parkinson's disease and neuropathic pain; '28th Camerino-Cyprus-Noordwijkerhout Symposium', May 16-20, 2010, Camerino, Italy, 57. http://www.unicam.it/farmacia/symposium/abstractBook2010.pdf.
31. Rozas G, Guerra MJ, Labandeira-Garcia JL, (1997). An automated rotarod method for quantitative drug-free evaluation of overall motor deficits in rat models of parkinsonism. Brain Res Brain Res Protoc 2: 75-84.
32. Schild OH, (1973). Drug Receptors., Rang HP, (ed). Macmillan: London.
33. Spagnolo B, Carra G, Fantin M, Fischetti C, Hebbes C, McDonald J, et al. (2007). Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl] methyl]-6,7,8,9-tetrah ydro-5H-benzocyclohepten-5-ol]: in vitro studies. J Pharmacol Exp Ther 321: 961-967.
34. Trapella C, Guerrini R, Piccagli L, Calo G, Carra G, Spagnolo B, et al. (2006). Identification of an achiral analogue of J-113397 as potent nociceptin/orphanin FQ receptor antagonist. Bioorg Med Chem 14: 692-704.
35. Viaro R, Sanchez-Pernaute R, Marti M, Trapella C, Isacson O, Morari M, (2008). Nociceptin/orphanin FQ receptor blockade attenuates MPTP-induced parkinsonism. Neurobiol Dis 30: 430-438.
36. Viaro R, Marti M, Morari M, (2010). Dual motor response to l-dopa and nociceptin/orphanin FQ receptor antagonists in 1-methyl-4-phenyl-1,2,5,6- tetrahydropyridine (MPTP) treated mice: paradoxical inhibition is relieved by D(2)/D(3) receptor blockade. Exp Neurol 223: 473-484.
37. Viaro R, Morari M, Franchi G, (2011). Progressive motor cortex functional reorganization following 6-hydroxydopamine lesioning in rats. J Neurosci 31: 4544-4554.
38. Visanji NP, de Bie RM, Johnston TH, McCreary AC, Brotchie JM, Fox SH, (2008). The nociceptin/orphanin FQ (NOP) receptor antagonist J-113397 enhances the effects of levodopa in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Mov Disord 23: 1922-1925.
39. Vitale G, Ruggieri V, Filaferro M, Frigeri C, Alboni S, Tascedda F, et al. (2009). Chronic treatment with the selective NOP receptor antagonist [Nphe 1, Arg 14, Lys 15]N/OFQ-NH 2 (UFP-101) reverses the behavioural and biochemical effects of unpredictable chronic mild stress in rats. Psychopharmacology (Berl) 207: 173-189.
40. Volta M, Mabrouk OS, Bido S, Marti M, Morari M, (2010a). Further evidence for an involvement of nociceptin/orphanin FQ in the pathophysiology of Parkinson's disease: a behavioral and neurochemical study in reserpinized mice. J Neurochem 115: 1543-1555.
41. Volta M, Marti M, McDonald J, Molinari S, Camarda V, Pela M, et al. (2010b). Pharmacological profile and antiparkinsonian properties of the novel nociceptin/orphanin FQ receptor antagonist 1-[1-cyclooctylmethyl-5-(1-hydroxy-1- methyl-ethyl)-1,2,3,6-tetrahydro-pyri din-4-yl]-3-ethyl-1,3-dihydro- benzoimidazol-2-one (GF-4). Peptides 31: 1194-1204.
42. Volta M, Viaro R, Trapella C, Marti M, Morari M, (2011). Dopamine-nociceptin/orphanin FQ interactions in the substantia nigra reticulata of hemiparkinsonian rats: involvement of D2/D3 receptors and impact on nigro-thalamic neurons and motor activity. Exp Neurol 228: 126-137.
43. Zaratin PF, Petrone G, Sbacchi M, Garnier M, Fossati C, Petrillo P, et al. (2004). Modification of nociception and morphine tolerance by the selective opiate receptor-like orphan receptor antagonist (-)-cis-1-methyl-7-[[4-(2,6- dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5- ol (SB-612111). J Pharmacol Exp Ther 308: 454-461.